NEW YORK, NY / ACCESSWIRE / February 24, 2016 / There is no better time to buy value than right now as smart moneymakers are raising cash to buy value plays on dips, near bottom. Volatility creates opportunity and right now we have identified Q BioMed (QBIO) as a winning opportunity. In our top group of Biotech and Healthcare stocks we consider QBIO as our best trade idea right now. Click here for the full details on how to make money from this winner:

http://valuableinvestment.com

Biotech stocks have been in flux for some time now, and the forthcoming results of the U.S. presidential elections are expected to impact the industry even more and on a very large scale. However, there are some positive hints of what may be in store for the Healthcare sector, and ValuableInvestment.com is directing its focus to some potential short- and long-term moneymakers. See how you can recover your portfolio by clicking on the link below:

http://valuableinvestment.com

Given the right timing and effective trade strategies, investors can achieve outstanding gains trading stocks in the Healthcare space. In fact, our members have reported generating huge profits since the start of the New Year by trading our unique ideas. We invite the community to be part of Wall Street's fastest growing online news portal today by signing up at:

http://valuableinvestment.com/register

ValuableInvestment.com today initiated its alert services on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Alder Biopharmaceuticals Inc. (NASDAQ: ALDR), and FibroGen Inc. (NASDAQ: FGEN). For those who did not see our report click here http://valuableinvestment.com and gain access to our Top Trade Idea Q BioMed (QBIO) that was announced on Monday.

BioCryst Pharmaceuticals Inc.'s stock saw a trading volume of 1.07 million shares. The stock finished Tuesday's session at $1.90, 12.04% lower. The Company's shares are trading below their 50-day moving average by 74.07%. Furthermore, BioCryst Pharmaceuticals' stock has a Relative Strength Index (RSI) of 19.40. Sign up and get the alert on BCRX at:

http://valuableinvestment.com/BCRX

On Tuesday, Anacor Pharmaceuticals Inc. recorded a trading volume of 848,112 shares, above its three months average volume of 721,220 shares. The stock ended the session at $66.97, down 11.25%. The Company's shares are trading 27.46% below its 50-day moving average. Moreover, shares of Anacor Pharmaceuticals have an RSI of 37.65. The complimentary alert on ANAC can be activated at:

http://valuableinvestment.com/ANAC

Alder Biopharmaceuticals Inc.'s stock recorded a trading volume of 756,145 shares, above its three months average volume of 601,130 shares. The stock saw a 9.14% correction to close the day at $19.29. Additionally, the Company's shares have an RSI of 28.19. Register for free on ValuableInvestment.com and access the latest strategies on ALDR at:

http://valuableinvestment.com/ALDR

On Tuesday, shares in FibroGen Inc. recorded a trading volume of 436,686 shares. The stock ended the day 7.27% lower at $17.98. The Company is trading below its 50-day moving average by 24.74%. Furthermore, shares of FibroGen have an RSI of 40.89. The complete trade setup on FGEN is available for free at:

http://valuableinvestment.com/FGEN

--

About ValuableInvestment.com:

Valuable Investment was founded in 2006 and has been successfully alerting investors and shareholders of the most profitable ways to earn a living on Wall Street. A decade is a very long time so we must be doing something right. We encourage everyone to come and try our strategy and see how we have been changing the foundation of research for years.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ValuableInvestment.com, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither valuableinvestment.com nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To read our disclosures, or for more information, visit http://valuableinvestment.com/

RESTRICTIONS

ValuableInvestment.com is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

E-mail: press@valuableinvestment.com

SOURCE: ValuableInvestment.com